Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueFinished GoodsLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOther Non-Current AssetsPayablesPrepaid AssetsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fennec Pharmaceuticals (FENC) Total Liabilities (2016 - 2025)

Fennec Pharmaceuticals' Total Liabilities history spans 15 years, with the latest figure at $35.1 million for Q4 2025.

  • For the quarter ending Q4 2025, Total Liabilities fell 30.97% year-over-year to $35.1 million, compared with a TTM value of $35.1 million through Dec 2025, down 30.97%, and an annual FY2025 reading of $35.1 million, down 30.97% over the prior year.
  • Total Liabilities for Q4 2025 was $35.1 million at Fennec Pharmaceuticals, down from $53.8 million in the prior quarter.
  • The five-year high for Total Liabilities was $66.2 million in Q1 2024, with the low at $2.9 million in Q1 2021.
  • Average Total Liabilities over 5 years is $34.3 million, with a median of $29.6 million recorded in 2023.
  • Year-over-year, Total Liabilities surged 340.15% in 2023 and then tumbled 30.97% in 2025.
  • Tracing FENC's Total Liabilities over 5 years: stood at $7.0 million in 2021, then skyrocketed by 321.48% to $29.5 million in 2022, then skyrocketed by 30.43% to $38.5 million in 2023, then soared by 32.04% to $50.8 million in 2024, then tumbled by 30.97% to $35.1 million in 2025.
  • Per Business Quant, the three most recent readings for FENC's Total Liabilities are $35.1 million (Q4 2025), $53.8 million (Q3 2025), and $52.3 million (Q2 2025).